Dr Zain Hasan, a Los Angeles-based anesthetist, warned his 636,000 followers on TikTok over the common drugs that could be ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the US, buying Eliquis, one of the most popular blood thinning medications, costs over three times more than in the next ...

NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

It's a disease that is most common in people in their 70s, more common in women, and almost never seen below the age of 50.

I was recently diagnosed with polymyalgia rheumatica after weeks of intense muscle pain. I’m a 67-year-old female in otherwise good health. My doctor prescribed prednisone, which immediately ...

Laboratory testing for inflammation, such as the C-reactive protein test and the erythrocyte sedimentation rate, are almost ...

过去几年，百时美施贵宝Bristol Myers Squibb（$百时美施贵宝(BMY)$）一直处于专利悬崖的坠落过程中。由于两款重要药物——抗癌药物Revlimid（曾经的畅销产品）和Abraxane失去专利保护，公司财务业绩随之下滑。所幸的是，百时美施贵宝已经反弹，营收重回增长轨道。 但值得注意的是，未来几年，这家制药巨头仍将面临更多的专利悬崖。 百时美施贵宝仍未摆脱困境 今年9月，百时美施贵 ...